Once written informed consent is obtained, the patient will be HLA-typed. They will be asked for 6-8 cc of blood for HLA-A2/A3/A24/A26 screening to be performed in a CLIA-certified laboratory at MD Anderson. Only HLA-A2/ HLA- A3/HLA-A24 or HLA-A26 positive patients will be enrolled in the trial. Those patients who are not HLA-A2,A3, A24, or A26 positive will be excluded.